Microdialysis probes calibration: Gradient and tissue dependent changes in No Net Flux and reverse dialysis methods

Quellec, Anne Le; Dupin, S.; Génissel, Patrick; Saivin, Sylvie; Marchand, Bernard; Houin, Georges

doi:10.1016/1056-8719(94)00049-a

Cited by 75 publications

(33 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the pharmacokinetic studies, each mouse received 10 mg/kg of MTX as an intravenous bolus and had collected serial blood samples [20 µl], from 2 to 360 min following drug administration, and 15 µL microdialysis samples from each probe at 15 min intervals. Each probe was perfused with aCSF at a rate of 1 µL/min, and were calibrated before drug administration using a retrodialysis technique [23]. Briefly, each probe was perfused with known concentrations of MTX [20 where C in = inlet analyte concentration, and out C out = mean of the outlet analyte concentration over 4 collection periods over 60 min.…”

Section: Methods Applicationmentioning

confidence: 99%

Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry

Guo

Wang

Liu

et al. 2007

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Methotrexate [MTX] is an anticancer agent that is widely used in a variety of human cancers including primary central nervous system lymphoma [PCNSL]. Important pharmacological properties that directly bear on the use of MTX in PCNSL, such as mechanisms that govern its uptake into brain tumors, are poorly defined, but are amenable to investigation in mouse models. In order to pursue such preclinical pharmacological studies, a rapid and sensitive liquid chromatography-tandem mass spectrometry [LC/MS/MS] method for the determination of MTX and its metabolite, 7-hydroxymethotrexate [7-OH MTX] in plasma and microdialysate samples from brain tumors and cerebrospinal fluid [CSF] is needed. The plasma assay was based on 10 µl samples and following a protein precipitation procedure enabled direct injection onto a LC/MS/MS system using positive electrospray ionization. A column switching technique was employed for desalting and the clean-up of microdialysate samples from brain tissues.The methods were validated for MTX and 7-OH MTX in both plasma and microdialysate samples from brain tumor and CSF, and produced lower limits of quantification [LLOQ] in plasma of 3.7 ng/ ml for MTX and 7.4 ng/ml for 7-OH MTX, and in microdialysate samples of 0.7 ng/ml for both MTX and 7-OH MTX. The utility of the method was demonstrated by estimation of pharmacokinetic [PK] and brain distribution properties of MTX and 7-OH MTX in conscious mice. The method has the advantages of low sample volume, rapid clean-up, and the simultaneous measurement of MTX and 7-OH MTX in plasma and brain tissues allowing detailed PK studies to be completed in individual mice.

show abstract

Section: Methods Applicationmentioning

confidence: 99%

Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry

Guo

Wang

Liu

et al. 2007

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

show abstract

“…Other theoretical papers were written by Chen et al in relation to active clearance processes and using one or dual probes (52,53). Articles comparing different recovery methods can be found in (67,78,79).…”

Section: Loss = Gain Methodsmentioning

confidence: 99%

Microdialysis as an Important Technique in Systems Pharmacology—a Historical and Methodological Review

Hammarlund‐Udenaes

2017

AAPS J

View full text Add to dashboard Cite

Abstract.Microdialysis has contributed with very important knowledge to the understanding of target-specific concentrations and their relationship to pharmacodynamic effects from a systems pharmacology perspective, aiding in the global understanding of drug effects. This review focuses on the historical development of microdialysis as a method to quantify the pharmacologically very important unbound tissue concentrations and of recent findings relating to modeling microdialysis data to extrapolate from rodents to humans, understanding distribution of drugs in different tissues and disease conditions. Quantitative microdialysis developed very rapidly during the early 1990s. Method development was in focus in the early years including development of quantitative microdialysis, to be able to estimate true extracellular concentrations. Microdialysis has significantly contributed to the understanding of active transport at the blood-brain barrier and in other organs. Examples are presented where microdialysis together with modeling has increased the knowledge on tissue distribution between species, in overweight patients and in tumors, and in metabolite contribution to drug effects. More integrated metabolomic studies are still sparse within the microdialysis field, although a great potential for tissue and disease-specific measurements is evident.

show abstract

“…Because in vivo probe recovery may be significantly different from in vitro recovery, we investigated in vivo recovery of topotecan in each animal using the retrodialysis method with or without gefitinib treatment (28,29). In vitro recovery studies done in our lab showed that topotecan lactone and carboxylate have the same recovery; for each form of topotecan.…”

Section: Methodsmentioning

confidence: 99%

Topotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor

et al. 2006

View full text Add to dashboard Cite

A potential strategy to increase the efficacy of topotecan to treat central nervous system (CNS) malignancies is modulation of the activity of ATP-binding cassette (ABC) transporters at the blood-brain and blood-cerebrospinal fluid barriers to enhance topotecan CNS penetration. This study focused on topotecan penetration into the brain extracellular fluid (ECF) and ventricular cerebrospinal fluid (CSF) in a mouse model and the effect of modulation of ABC transporters at the bloodbrain and blood-cerebrospinal fluid barriers by a tyrosine kinase inhibitor (gefitinib). After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 F 0.04 and 0.61 F 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 F 0.10 and 1.30 F 0.13, respectively. To study the effect of gefitinib on topotecan CNS penetration, 200 mg/kg gefitinib was administered orally 1 hour before 4 mg/kg topotecan i.v. The brain ECF to plasma AUC ratio of unbound topotecan lactone increased by 1.6-fold to 0.35 F 0.04, which was significantly different from the ratio without gefitinib (P < 0.05). The ventricular CSF to plasma AUC ratio significantly decreased to 0.98 F 0.05 (P < 0.05). Breast cancer resistance protein 1 (Bcrp1), an efficient topotecan transporter, was detected at the apical aspect of the choroid plexus in FVB mice. In conclusion, topotecan brain ECF penetration was lower compared with ventricular CSF penetration. Gefitinib increased topotecan brain ECF penetration but decreased the ventricular CSF penetration. These results are consistent with the possibility that expression of Bcrp1 and P-glycoprotein at the apical side of the choroid plexus facilitates an influx transport mechanism across the blood-cerebrospinal fluid barrier, resulting in high topotecan CSF penetration. (Cancer Res 2006; 66(23): 11305-13)

show abstract

Microdialysis probes calibration: Gradient and tissue dependent changes in No Net Flux and reverse dialysis methods

Cited by 75 publications

References 15 publications

Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry

Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry

Microdialysis as an Important Technique in Systems Pharmacology—a Historical and Methodological Review

Topotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor

Contact Info

Product

Resources

About